CTVA
Corteva, Inc.
$76.14
+1.71%
$50.9B
No data for this timeframe.
Vol
Market Cap$50.9B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (70%)
Inst. Holders50 funds
Inst. Value$35.2B
Inst. Activity32 buys / 18 sells
Reddit Sentiment50° Neutral
SEC Reports4
Congressional1 trades
Recent Activity
Jun 8, 2026
short_volume
Short Volume: CTVA — 67.9% short (0.7M / 1.0M)
Short: 710,986 | Exempt: 2,159 | TRF Vol: 1,046,369 | Short Ratio: 67.9% | Off-exchange volume (dark
Jun 3, 2026
SEC
Luther C. Kissam IV, the CEO of Corteva's Crop Protection Business, filed a Form 3 initial statement of beneficial owner
3 — Impact 2/10
Jun 1, 2026
Insider
KISSAM LUTHER C IV was granted 24,138 shares
CEO, Crop Protection Business
May 5, 2026
SEC
Corteva reported strong Q1 2026 results with net sales up 11% YoY to $4.905B and operating EPS of $1.50, significantly b
8-K — Impact 7/10
Apr 30, 2026
Insider
Engel Klaus A surrendered for taxes 906 shares
Director @ $81.01 ($73.4K)
Apr 30, 2026
Insider
Giesselman Janet Plaut was granted 95.667 shares
Director @ $81.01 ($7.7K)
Apr 14, 2026
SEC
Corteva announced a major leadership transition ahead of its planned spin-off, appointing Luke Kissam as CEO of the new
8-K — Impact 5/10
Inst.
Capital World Investors — ADD
35,998,047 shares ($3.0B)
Price Targets
$90.05
+18.3% upside
Buy
Current $76.14
Low $77.00
Median $90.00
High $100.00
21 analysts
$77.00
$100.00
Analyst Ratings
7Strong Buy
14Buy
9Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Jun 9, 2026 | UBS | MAINTAIN | Neutral → Neutral |
| May 28, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| May 7, 2026 | UBS | MAINTAIN | Neutral → Neutral |
| May 7, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.23 ▼ -0.5% | $2.10 — $2.33 | 1% YoY | 16 |
| Next Q | $-0.28 | $-0.39 — $-0.15 | -22% YoY | 16 |
| Current FY | $3.74 | $3.55 — $4.03 | 12% YoY | 22 |
| Next FY | $3.22 ▼ -3.3% | $2.57 — $3.67 | 21% YoY | 4 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $4.6B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.7B | — |
| STATE STREET CORP | $3.0B | — |
| Capital World Investors | $3.0B | ADD |
| FMR LLC | $2.9B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | KISSAM LUTHER | A | $0.00 |
| Apr 30, 2026 | Engel Klaus | F | $73.4K |
| Apr 30, 2026 | Giesselman Janet | A | $7.7K |
| Apr 30, 2026 | Lutz Marcos | F | $73.4K |
| Apr 30, 2026 | Nayyar Nayaki | A | $32.5K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
Congressional Trades
1 members: 0 buys, 1 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Gary Peters | D | SELL | $15,001 - $50,000 |
50 institutional holders with $35.2B total value (421,546,070 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 54,710,452 | $4.6B | 13.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 44,075,854 | $3.7B | 10.5% | — |
| 3 | STATE STREET CORP | 36,138,039 | $3.0B | 8.6% | — |
| 4 | Capital World Investors | 35,998,047 | $3.0B | 8.6% | ADD +68.6% |
| 5 | FMR LLC | 34,971,900 | $2.9B | 8.3% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 30,061,788 | $2.5B | 7.2% | — |
| 7 | FRANKLIN RESOURCES INC | 21,794,607 | $1.8B | 5.2% | — |
| 8 | Aristotle Capital Management, LLC | 18,833,712 | $1.6B | 4.5% | — |
| 9 | HARRIS ASSOCIATES L P | 16,656,133 | $1.4B | 4.0% | — |
| 10 | Invesco Ltd. | 10,862,534 | $909.3M | 2.6% | — |
| 11 | MORGAN STANLEY | 9,931,302 | $831.3M | 2.4% | — |
| 12 | WCM INVESTMENT MANAGEMENT, LLC | 8,712,618 | $722.7M | 2.1% | — |
| 13 | ROYAL BANK OF CANADA | 7,458,624 | $624.4M | 1.8% | — |
| 14 | JANUS HENDERSON GROUP PLC | 7,254,186 | $607.2M | 1.7% | — |
| 15 | GOLDMAN SACHS GROUP INC | 6,913,972 | $578.8M | 1.6% | — |
| 16 | WELLS FARGO & COMPANY/MN | 6,147,075 | $514.6M | 1.5% | — |
| 17 | Legal & General Group Plc | 5,665,056 | $474.2M | 1.3% | — |
| 18 | BANK OF AMERICA CORP /DE/ | 5,253,039 | $439.7M | 1.2% | — |
| 19 | DIMENSIONAL FUND ADVISORS LP | 4,771,253 | $399.4M | 1.1% | — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 4,500,975 | $376.8M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Capital World Investors | ADD | 21,355,189 | 35,998,047 | +68.6% | $3.0B | 2026-Q1 |
| M&T BANK CORP | DOUBLED | 28,910 | 1,825,753 | +6215.3% | $152.8M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 888,407 | 1,622,421 | +82.6% | $135.8M | 2026-Q1 |
| Ninety One UK Ltd | ADD | 858,349 | 1,274,709 | +48.5% | $106.7M | 2026-Q1 |
| Independent Franchise Partners LLP | NEAR_EXIT | 10,495,388 | 1,188,896 | -88.7% | $99.5M | 2026-Q1 |
| BRANDES INVESTMENT PARTNERS, LP | TRIM | 2,312,515 | 895,553 | -61.3% | $75.0M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 856,294 | 616,892 | -28.0% | $51.6M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | TRIM | 1,061,763 | 596,194 | -43.8% | $49.9M | 2026-Q1 |
| Gotham Asset Management, LLC | ADD | 344,118 | 575,102 | +67.1% | $48.1M | 2026-Q1 |
| Allianz Asset Management GmbH | DOUBLED | 106,952 | 559,102 | +422.8% | $46.8M | 2026-Q1 |
| FIL Ltd | DOUBLED | 275,533 | 558,911 | +102.8% | $46.8M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | TRIM | 982,242 | 531,478 | -45.9% | $44.5M | 2026-Q1 |
| Erste Asset Management GmbH | DOUBLED | 8,932 | 510,032 | +5610.2% | $42.3M | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 903,046 | 499,517 | -44.7% | $41.8M | 2026-Q1 |
| Capital International, Inc./CA/ | ADD | 259,963 | 428,001 | +64.6% | $35.8M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 178,392 | 423,647 | +137.5% | $35.5M | 2026-Q1 |
| MACQUARIE GROUP LTD | ADD | 232,253 | 310,893 | +33.9% | $26.0M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 157,801 | 234,551 | +48.6% | $19.6M | 2026-Q1 |
| Tredje AP-fonden | NEW | — | 216,694 | — | $18.1M | 2026-Q1 |
| TORONTO DOMINION BANK | TRIM | 289,317 | 200,428 | -30.7% | $16.8M | 2026-Q1 |
| Trexquant Investment LP | NEW | — | 198,964 | — | $16.7M | 2026-Q1 |
| Banco Santander, S.A. | TRIM | 238,792 | 178,376 | -25.3% | $14.9M | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 172,072 | 248,419 | +44.4% | $12.4M | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 95,473 | 142,713 | +49.5% | $11.9M | 2026-Q1 |
| Zurich Insurance Group Ltd/FI | NEW | — | 136,835 | — | $11.5M | 2026-Q1 |
20 unique insiders with 46 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | KISSAM LUTHER C IV | CEO, Crop Protection Business | AWARD | 24,138 | — | — |
| Apr 30, 2026 | Engel Klaus A | Director | TAX W/H | 906 | $81.01 | $73.4K |
| Apr 30, 2026 | Giesselman Janet Plaut | Director | AWARD | 95.667 | $81.01 | $7.7K |
| Apr 30, 2026 | Lutz Marcos M | Director | TAX W/H | 906 | $81.01 | $73.4K |
| Apr 30, 2026 | Nayyar Nayaki R | Director | AWARD | 401.185 | $81.01 | $32.5K |
| Apr 28, 2026 | PAGE GREGORY R | Director | AWARD | 3,870 | — | — |
| Apr 28, 2026 | Engel Klaus A | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Gilson Jean-Marc | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Giesselman Janet Plaut | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Grimes Karen H. | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Lutz Marcos M | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Preete Kerry J | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Nayyar Nayaki R | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Policinski Christopher J. | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | Ward Pat | Director | AWARD | 2,350 | — | — |
| Apr 28, 2026 | EVERITT DAVID C | Director | AWARD | 2,350 | — | — |
| Feb 28, 2026 | Grimm Audrey | SVP, Chief People Officer | TAX W/H | 285 | $80.12 | $22.8K |
| Feb 28, 2026 | Eathington Samuel R | See Remarks | TAX W/H | 471 | $80.12 | $37.7K |
| Feb 28, 2026 | O'Connor Judd M | EVP, Seed Business Unit | TAX W/H | 188 | $80.12 | $15.1K |
| Feb 28, 2026 | King Robert D. | EVP, Crop Protection Business | TAX W/H | 574 | $80.12 | $46.0K |
| Feb 28, 2026 | TITUS BRIAN | See Remarks | TAX W/H | 111 | $80.12 | $8.9K |
| Feb 28, 2026 | Magro Charles V. | Chief Executive Officer | TAX W/H | 4,958 | $80.12 | $397.2K |
| Feb 24, 2026 | Magro Charles V. | Chief Executive Officer | AWARD | 108,376 | — | — |
| Feb 24, 2026 | O'Connor Judd M | EVP, Seed Business Unit | AWARD | 14,173 | — | — |
| Feb 24, 2026 | King Robert D. | EVP, Crop Protection Business | AWARD | 15,006 | — | — |
| Feb 24, 2026 | TITUS BRIAN | See Remarks | AWARD | 2,085 | — | — |
| Feb 24, 2026 | Grimm Audrey | SVP, Chief People Officer | AWARD | 11,255 | — | — |
| Feb 24, 2026 | Eathington Samuel R | See Remarks | AWARD | 14,173 | — | — |
| Feb 24, 2026 | Johnson Jennifer Amy | SVP, Chief Legal Officer | AWARD | 12,922 | — | — |
| Feb 24, 2026 | Johnson David Paul | EVP, Chief Financial Officer | AWARD | 24,112 | — | — |
| Feb 20, 2026 | Grimm Audrey | SVP, Chief People Officer | TAX W/H | 387 | $76.31 | $29.5K |
| Feb 20, 2026 | Magro Charles V. | Chief Executive Officer | TAX W/H | 6,026 | $76.31 | $459.8K |
| Feb 20, 2026 | King Robert D. | EVP, Crop Protection Business | TAX W/H | 576 | $76.31 | $44.0K |
| Feb 20, 2026 | O'Connor Judd M | EVP, Seed Business Unit | TAX W/H | 247 | $76.31 | $18.8K |
| Feb 20, 2026 | Eathington Samuel R | See Remarks | TAX W/H | 572 | $76.31 | $43.6K |
| Feb 20, 2026 | TITUS BRIAN | See Remarks | TAX W/H | 132 | $76.31 | $10.1K |
| Feb 20, 2026 | TITUS BRIAN | See Remarks | EXERCISE | 4,311 | — | — |
| Feb 18, 2026 | Grimm Audrey | SVP, Chief People Officer | TAX W/H | 399 | $76.59 | $30.6K |
| Feb 18, 2026 | Eathington Samuel R | See Remarks | TAX W/H | 524 | $76.59 | $40.1K |
| Feb 18, 2026 | Johnson David Paul | EVP, Chief Financial Officer | TAX W/H | 704 | $76.59 | $53.9K |
| Feb 18, 2026 | O'Connor Judd M | EVP, Seed Business Unit | TAX W/H | 352 | $76.59 | $27.0K |
| Feb 18, 2026 | King Robert D. | EVP, Crop Protection Business | TAX W/H | 526 | $76.59 | $40.3K |
| Feb 18, 2026 | Magro Charles V. | Chief Executive Officer | TAX W/H | 5,319 | $76.59 | $407.4K |
| Feb 18, 2026 | TITUS BRIAN | See Remarks | TAX W/H | 113 | $76.59 | $8.7K |
| Jan 30, 2026 | Nayyar Nayaki R | Director | AWARD | 446.429 | $72.80 | $32.5K |
| Jan 30, 2026 | Giesselman Janet Plaut | Director | AWARD | 106.456 | $72.80 | $7.7K |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
NEUTRAL
3
2/10
Luther C. Kissam IV, the CEO of Corteva's Crop Protection Business, filed a Form 3 initial statement
Jun 3, 2026
BULLISH
8-K
7/10
Corteva reported strong Q1 2026 results with net sales up 11% YoY to $4.905B and operating EPS of $1
May 5, 2026
NEUTRAL
8-K
5/10
Corteva announced a major leadership transition ahead of its planned spin-off, appointing Luke Kissa
Apr 14, 2026
NEUTRAL
DEFA14A
3/10
Corteva, Inc. has filed a definitive proxy statement for its 2026 Annual Meeting, where shareholders
Mar 19, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (70% buy). Based on 30 analysts: 7 strong buy, 14 buy, 9 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$90.05 mean target
+18.3% upside
Buy (1.73)
$77.00 Low
$100.00 High
| Metric | Value |
|---|---|
| Current Price | $76.14 |
| Target Low | $77.00 |
| Target Mean | $90.05 |
| Target Median | $90.00 |
| Target High | $100.00 |
| # Analysts | 21 |
| Recommendation | Buy (1.73) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$2.23 | $2.10 | $2.33 | 1.1% | -0.5% | 1↑ 13↓ | $6.6B | 1.8% | 16 |
| Next Q 2026-09-30 |
$-0.28 | $-0.39 | $-0.15 | -21.8% | -0.2% | 2↑ 12↓ | $2.7B | 2.8% | 16 |
| Current FY 2026-12-31 |
$3.74 | $3.55 | $4.03 | 11.9% | +0.2% | 18↑ 3↓ | $18.3B | 5.1% | 22 |
| Next FY 2027-12-31 |
$3.22 | $2.57 | $3.67 | 20.7% | -3.3% | 2↑ 2↓ | $18.9B | 3.4% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.225 | |
| 7d ago | $2.225 | -0.000 |
| 30d ago | $2.236 | -0.011 |
| 60d ago | $2.325 | -0.100 |
| 90d ago | $2.321 | -0.096 |
10 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jun 9, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| May 28, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| May 7, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Apr 24, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 21, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 9, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Mar 31, 2026 | Argus Research | MAINTAIN | Buy | Buy |
| Feb 17, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 5, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 5, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 5, 2026 | JP Morgan | DOWNGRADE | Overweight | Neutral |
| Jan 27, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jan 21, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Jan 21, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 16, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Dec 18, 2025 | Citigroup | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 14 | 9 | 0 | 0 | 70% | |
| May 1, 2026 | 7 | 15 | 8 | 0 | 0 | 73% | |
| Apr 1, 2026 | 7 | 15 | 8 | 0 | 0 | 73% | |
| Mar 1, 2026 | 7 | 15 | 9 | 0 | 0 | 71% | |
| Feb 1, 2026 | 7 | 17 | 7 | 0 | 0 | 77% | |
| Jan 1, 2026 | 7 | 17 | 7 | 0 | 0 | 77% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 0 buys, 1 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Gary Peters | D | SENATE | SELL | $15,001 - $50,000 | Corteva Inc | May 11, 2026 (19d) |
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Investing in agriculture/construction
▲ 1
💬 0
⚡ 0.5
Jun 8, 2026
short_volume
Short Volume: CTVA — 67.9% short (0.7M / 1.0M)
Short: 710,986 | Exempt: 2,159 | TRF Vol: 1,046,369 | Short Ratio: 67.9% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: CTVA — 64.1% short (0.6M / 0.9M)
Short: 606,373 | Exempt: 433 | TRF Vol: 946,718 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: CTVA — 66.2% short (0.6M / 0.9M)
Short: 595,312 | Exempt: 206 | TRF Vol: 898,891 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: CTVA — 71.7% short (0.7M / 0.9M)
Short: 675,455 | Exempt: 1,925 | TRF Vol: 942,548 | Short Ratio: 71.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: CTVA — 72.7% short (0.6M / 0.9M)
Short: 641,227 | Exempt: 5,589 | TRF Vol: 882,624 | Short Ratio: 72.7% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: CTVA — 65.0% short (0.6M / 0.9M)
Short: 594,481 | Exempt: 162 | TRF Vol: 914,680 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: CTVA — 69.4% short (0.6M / 0.8M)
Short: 562,094 | Exempt: 997 | TRF Vol: 809,504 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: CTVA — 72.6% short (0.6M / 0.9M)
Short: 640,703 | Exempt: 1,802 | TRF Vol: 883,087 | Short Ratio: 72.6% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: CTVA — 73.0% short (0.8M / 1.2M)
Short: 846,968 | Exempt: 1,300 | TRF Vol: 1,159,787 | Short Ratio: 73.0% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: CTVA — 62.3% short (0.4M / 0.6M)
Short: 402,598 | Exempt: 335 | TRF Vol: 645,720 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: CTVA — 70.4% short (0.5M / 0.7M)
Short: 469,277 | Exempt: 1,289 | TRF Vol: 666,311 | Short Ratio: 70.4% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: CTVA — 67.3% short (0.8M / 1.2M)
Short: 815,436 | Exempt: 135 | TRF Vol: 1,211,660 | Short Ratio: 67.3% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CTVA — 61.0% short (0.7M / 1.1M)
Short: 651,170 | Exempt: 518 | TRF Vol: 1,068,146 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CTVA — 72.6% short (0.7M / 0.9M)
Short: 657,573 | Exempt: 513 | TRF Vol: 906,253 | Short Ratio: 72.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: CTVA — 3.9M shares, 84,712 trades
Week starting 2026-05-18. Total ATS volume: 3,907,947 shares across 84,712 trades.
Feb 24, 2026
Clinical Trial
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus
Phase Phase 3 — COMPLETED
Feb 24, 2026
Clinical Trial
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication
Phase Phase 3 — COMPLETED
Feb 24, 2026
FDA
Clopidogrel
WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE The effectiveness of clopidogrel bisulfate r